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CSF tau and Aβ42 are considered as important markers to diagnose Alzheimer’s disease in early stages. Hence, it is important to
assess their status in diﬀerent types of dementia. The main objective of this study was to assess whether these CSF biomarkers
c a nb eu s e dt om a k et h ed i ﬀerential diagnosis of AD. In the present study, articles published from 1998 till 2009 were taken and
meta-analysis was performed to clarify the consistency in trends of biomarkers- CSF tau and Aβ42 in AD and other dementias and
whether the same can be used as diagnostic biomarkers for its early diagnosis. 11 out of 60 for CSF tau and 07 out of 40 for CSF
Aβ42, dementia case-control studies were selected for ﬁnal analysis. Descriptive statistics shows that median eﬀect size (raw mean
diﬀerence) of CSF tau was 429pg/mL (range: 32 to 910pg/mL) in AD whereas in Dementia due to other causes (DOC) studies
it was 69pg/mL (range: −53 to 518pg/mL). Similarly the median eﬀect size of CSF Aβ42 levels was −442pg/mL (range: −652 to
−41.200pg/mL) whereas in DOC studies it was −193pg/mL (range: −356 to −33pg/mL).
1.Introduction
With the increase in life expectancy, Alzheimer’s disease,
considered as disease of aging population, has become a
major public health problem adding burden to societal
costs each year for chronic care and lost productivity in
developed and developing countries [1]. Presently, diagnosis
of AD is primarily based on the exclusion of other causes
of dementia on clinical trials. However, it is not of much
help due to overlapping of clinical features of AD with
other dementias in early stages. Attempts have been made
in the last 4-5 decades to develop and validate speciﬁc
biological markers which are able to detect the fundamental
neuropathological changes occurring in AD in its early stage
with high sensitivity (≥80%) and distinguish it from other
dementias [2]. Based on these studies, the combination of
total tau and amyloid β42 (Aβ42) was identiﬁed as being
among the most promising and informative AD markers to
be of use in early diagnosis and as surrogate biomarkers
in CSF [2–4]. Increased levels of tau in CSF have been
suggested to reﬂect neuronal and axonal degeneration [5]
whereasreducedCSFlevelsofAβ42 mightreﬂectextracellular
accumulation of Aβ42 into insoluble senile plaques in the
AD brain [6, 7]. However, high CSF concentration of total
tau has also been reported in mild cognitive impairment
[8], as well as in vascular dementia (VaD) [2, 9–11]. The
comorbidity ofADandotherdementiascanfurthergenerate
problems. Though studies have reported highly accurate
diﬀerentiation between AD and normal controls with high
sensitivity (50–94%) and speciﬁcity (83–100%) [12], CSF-
based diﬀerentiation of AD with VaD remains a challenge
with speciﬁcity of 48% only [13]. Also, AD can be associated
withotherneurodegenerativediseaseslikeLewybodydisease
and progressive supranuclear palsy.
In view of the necessity of identifying biomarkers for
diﬀerentiation of AD from other dementia disorders, the
combination of CSF tau and Aβ42 has been advocated as
diagnostic marker. However, before the diagnostic utility of
CSF tau and Aβ42 concentration for diagnosis of AD can
be established, it is crucial to assess whether the eﬀect sizes
of the published studies reported in the last ﬁfteen years
show consistent trends in their levels or not in AD cases as
compared to controls. The consistency in eﬀect size of tau
and Aβ42 levels of these studies was explored by advanced2 International Journal of Alzheimer’s Disease
statistical method meta-analysis with three main goals: (i)
to test whether the results of studies are homogeneous,
(ii) to obtain a global index about the eﬀect magnitude
of the studied relation, joined to a conﬁdence interval and
its signiﬁcance, and (iii) to identify possible variables or
characteristics moderating the results obtained if there is
heterogeneity among studies [14]. In the present study,
studies conducted from 1995 till 2009 were taken and meta-
analysis was performed to clarify the consistency in trends of
biomarkers CSF tau and Aβ42 in diﬀerent types of dementias
and whether the same can be used as diagnostic biomarkers
for early diagnosis of AD.
2.MaterialsandMethods
2.1. Search Strategy. Meta-analysis was performed for CSF
tau and Aβ42 levels, by calculating and combining the
eﬀect sizes (raw mean diﬀerence), their standard error, and
95% conﬁdence interval after extracting mean, standard
deviation, and sample size from 11 CSF studies. 11 studies
out of 60 studies for CSF tau levels and 7 studies out of 41
studies were selected for CSF Aβ42 levels in dementias from
1996 to 2009 using keywords CSF biomarkers in Alzheimer’s
disease, tau levels in Alzheimer’s disease, and Aβ42 levels in
Alzheimer’s disease.
2.2. Exclusion Criteria. Studies were excluded if they were
not in English language, did not provide data for controls,
did not mention the diagnostic criteria for AD, and did not
report the SD of the mean CSF tau and Aβ42 level or their
units were not in pg/mL. Also, studies where tau and Aβ42
were measured by methods other than sandwich enzyme
linked immunosorbant assay were excluded. Only those
studies were undertaken in which CSF tau and Aβ42 levels
were measured in AD and other dementias (vascular demen-
tia, Parkinson’s disease-associated dementia, and Lewy body
dementia) in controls using Innotest kit from Innogenetics,
Belgium. All the studies included had interday and intraday
variation less than 10%. Other-dementias group was named
dementia due to other causes (DOC). All the values were
expressed in pg/mL.
2.3. Statistical Analysis. The raw mean diﬀerence (unstan-
dardized) was used for calculating the eﬀect size of each
study.Theheterogeneityineﬀectsizeofbothparameters(tau
and Aβ42), which may occur from study to study and is one
of the serious issues of any meta-analysis, was explored with
the help of three statistical tools: (1) test of signiﬁcance (Q
statistics), (2) between-studies variance (T2), and (3) degree
of heterogeneity (I2). An appropriate model (ﬁxed eﬀect
versus random eﬀectmodel) forgetting the pooled eﬀectsize
wasdecidedafterevaluatingtheheterogeneityineﬀectsizeof
all the included studies.
The graphical method (Forest plot) has been applied for
studying the variability between the eﬀect sizes of individual
studies. In Forest plot, each study eﬀect size and respective
conﬁdence interval (CI) were plotted on one set of axis along
with pooled estimate of eﬀect size, together with its CI.
All the statistical analysis was done using the Meta-
analysis report software (Version: Beta3.13) downloaded
from the web site on 05.10.10.
3. Results
As CSF tau and Aβ42 levels have emerged as two biomarkers
for early diagnosis of dementia, in this paper, meta-analysis
of published studies for CSF tau and Aβ42 level has been
carried out to establish the role of combination of two
biomarkers in Alzheimer’s disease and dementia due to other
causes (DOC).
3.1. Meta-Analysis of CSF Tau Level in Dementia. Am e t a -
analysis was performed in 11 published studies of CSF tau in
AD and DOC, selected from total of 60 studies. Out of total
published studies included in meta-analysis of CSF tau levels
inDOC5publishedstudieswereofvasculardementia(VaD)
[7, 18, 22–24], 2 of Parkinson’s disease-associated dementia
(PDD) [15, 20], 1 of mixed dementia [16], and the rest were
non-AD dementia (non-ADD) [17, 19]. Out of 11 studies,
only two studies in AD [15, 23] and one study in DOC [23]
were having matched controls.
Table 1 shows that details of 11 included studies along
with mean, SD, and sample size (N) of CSF tau level for cases
and controls. Eﬀect size (raw mean diﬀerence), standard
error, 95% conﬁdence interval and weight for each included
study were calculated. None of studies show eﬀect size zero
in both group (Alzheimer’s disease and DOC).
Table 2 showsthatmediansamplesize(case+control)in
11 Alzheimer’s disease studies of CSF tau level was 67 (range:
30–142) whereas it was 49 (range: 26–134) in dementia-due-
to-other-causes studies. The median eﬀect size (raw mean
diﬀerence) of tau level in Alzheimer’s disease studies was
429pg/mL (range: 32 to 910pg/mL) whereas in dementia-
due-to-other-causes studies it was 69pg/mL (range: −53 to
518pg/mL). In Alzheimer’s disease, CSF tau level is quite
high as compared to DOC.
Table 3 shows the estimated pooled eﬀect size of CSF tau
level and its 95% conﬁdence interval (CI) of 11 included
studies for both groups. Between-studies variance, degree of
heterogeneity with 95% CI, Q statistics, degree of freedom,
and P value were also shown in the same tables. From
Table 3, it can be seen that between-studies variance, degree
of heterogeneity, and Q statistics all three approaches clearly
indicate that variability in CSF tau estimates across the
studies was too high and random eﬀect model for pooling
of CSF tau estimates is the only choice. After applying
random eﬀect model for pooling of estimates, the pooled
estimate of CSF tau in Alzheimer’s disease studies was
414.073pg/mL (CI: 237.170–590.975) while it was quiet low
as 83.500pg/mL (CI: 36.406–130.595) in dementia-due-to-
other-causes studies.
Forestplot(Figure 1(a))showsthatoutof11Alzheimer’s
disease studies, eﬀect size (raw mean diﬀerence) of 6 studies
[13, 15, 18, 20, 22, 23] was more than pooled estimate
of eﬀect size, and in 5 studies [16, 17, 19, 21, 24], it was
belowthepooledeﬀectsize,whereasoutof11dementia-due-
to-other-causes studies (Figure 1(b)), 5 studies were havingInternational Journal of Alzheimer’s Disease 3
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Table 2: Descriptive statistics of CSF tau studies in Alzheimer’s disease and dementia due to other causes.
CSF tau level (pg/mL) Alzheimer’s disease Dementia due to other causes
Median Range Median Range
Sample size 67 30–142 49 26–134
Eﬀect size 429 32.020–910 69 −53.300–518
Table 3: Pooled estimate of eﬀect size with 95% CI, test of signiﬁcance and magnitude of heterogeneity of CSF tau studies in Alzheimer’s
disease and Dementia due to other causes.
Statistics Alzheimer’s disease Dementia due to other causes
Pooled estimate of CSF tau (pg/mL) 414.073 83.500
95% CI of pooled estimate (pg/mL) 237.170–590.975 36.406–130.595
Between-studies variance (T2) 85013.958 4343.165
Degree of heterogeneity (I2) 97.9% 82.4%
95% CI of I2 97.2%–98.4% 69.7%–89.7%
Q statistics 467.756 56.738
DF 10 10
P value 0.000 0.000
individual eﬀect size more than pooled estimate of eﬀect size
[13, 16, 18, 22, 23], while in 6 studies, individual eﬀect size
was below the pooled eﬀect size [15, 17, 19–21, 24].
3.2. Meta-Analysis of CSF Amyloid β42 Level in Dementia. A
meta-analysis was performed in 7 published studies of CSF
tau in AD and DOC, selected from total of 41 studies. Out
of total published studies included in meta-analysis of CSF
Aβ42 levels in DOC 3 published studies were of vascular
dementia (VaD) [13, 22, 23], 1 of Parkinson’s disease-
associated dementia (PDD) [20], 1 of semantic dementia
[21], and the rest were non-AD dementia (non-ADD) [17,
19].
Table 4 showsthatdetailsof7includedstudiesalongwith
mean,SD,andsamplesize(N)ofCSFAβ42 levelforcasesand
controls. Eﬀect size (raw mean diﬀerence), standard error,
95% conﬁdence interval, and weight for each included study
were calculated. None of studies show eﬀect size zero in
both group (Alzheimer’s disease and dementia due to other
causes).
Table 5 showsthatmediansamplesize(case+control)in
7Alzheimer’s disease studies of CSFAβ42 levelwas73 (range:
30–142) whereas it was 41 (range: 26–134) in dementia-
due-to-other causes studies. The median eﬀect size (raw
mean diﬀerence) of Aβ42 level in Alzheimer’s disease studies
was −442pg/mL (range: −652 to −41.200pg/mL) whereas
in dementia-due-to-other causes studies it was −193pg/mL
(range: −356 to −33pg/mL). In Alzheimer’s disease, median
CSF Aβ42 level is quite low as compared to DOC.
Table 6 shows the pooled eﬀect size of CSF Aβ42
level and its 95% conﬁdence interval (CI) of 7 included
studies. Between-studies variance, degree of heterogeneity
with 95% CI, Q statistics, degree of freedom, and P
value were also shown in the same tables. From Table 6,
it can be seen that between-studies variance, degree of
heterogeneity, and Q statistics all three approaches clearly
indicate that variability in CSF Aβ42 estimates across the
studies was too high and random eﬀect model for pooling
of CSF Aβ42 estimates is the only choice. After applying
random eﬀect model for pooling of estimates, the pooled
estimate of CSF Aβ42 in Alzheimer’s disease studies was
−363.926pg/mL(CI:−542.007–−185.845)whileitwasquiet
high as −170.743pg/mL (CI: −256.912–−84.574) in DOC
studies.
Forest plot (Figure 2(a)) shows that out of 7 Alzheimer’s
disease studies, eﬀect size (raw mean diﬀerence) of 2 studies
was more than pooled estimate of eﬀect size [19, 21] and,
in 05 studies, it was less than the pooled eﬀect size [13, 17,
20, 22, 23]. Of 7 DOC studies (Figure 2(b)), 02 studies were
also having individual eﬀect size more than pooled estimate
of eﬀect size [19, 21] while in 05 studies individual eﬀect size
was below the pooled eﬀect size [13, 17, 20, 22, 23].
Funnelplotsshowedclearexistenceofpublicationbiasin
both groups.
4. Discussion
Diagnostic markers for AD have been sought for many
years for its early diagnosis and diﬀerentiating it from other
types of dementias. Distinguishing between the two most
common forms of dementias, AD and VaD, is one of the
most challenging diﬀerential diagnoses in geriatrics OPD
and is very crucial also because the therapeutic strategies are
very diﬀerent. With the development of cholinergic-based
treatments for AD, there is great emphasis on the need for
its early and accurate diagnosis to allow initiation of therapy
when it will be of most beneﬁt to the patients [17]. CSF
biomarkers tau and Aβ42 combined together have emerged
as such diagnostic markers for early diagnosis of AD.
Although combination of CSF tau and Aβ42 yields a highly
accuratediﬀerentiationbetweenADandcontrols,CSF-based
diﬀerentiation of AD from other dementias especially VaDInternational Journal of Alzheimer’s Disease 5
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Figure 1: (a) CSF tau level in Alzheimer’s disease. (b) CSF tau level in dementia due to other causes.
remains highly challenging as it has low speciﬁcity for the
same [13].
4.1. Meta-Analysis of CSF Tau Level. A meta-analysis per-
formed in 11 published studies of CSF tau in diﬀerent types
ofdementiasshowedhighlevelsoftauinADinallthestudies
whereas 2 studies showed low levels in DOC as compared
to controls. A number of studies have found a signiﬁcant
increase in CSF tau levels in AD and DOC as compared with
normal ageing [25–27].
Table 2 shows that raw mean diﬀerence of CSF tau levels
in AD group was much higher than that in DOC group
signifying that levels of tau in CSF in AD cases rise much
higher than in DOC. This ﬁnding supports the studies
showing much higher sensitivity and speciﬁcity of CSF tau
levelsin distinguishing theADpatients fromcontrolsubjects
as compared to non-AD dementias [16]a n dV a D[ 13].
The assessment of the heterogeneity in meta-analysis
is a crucial issue because the presence versus absence of
true heterogeneity (between-studies variability) can aﬀect
the choice of statistical model. There can be two sources
of variability leading to heterogeneity in a set of studies
in a meta-analysis. First, variability due to sampling error
(within-studyvariability)isalwayspresentinameta-analysis
because every single study uses diﬀerent samples. The other
source of variation is due to heterogeneity among the
population eﬀect sizes estimated by the individual studies
(between-studies variability). It may be due to variation in
the characteristics of the samples, treatment and the design
qualityofthestudy [27].Inthepresentstudy,threestatistical
methodswereappliedtoexplorethetrueheterogeneity.They6 International Journal of Alzheimer’s Disease
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Table 5: Descriptive statistics of CSF Aβ42 studies in Alzheimer’s disease and dementia due to other causes.
CSF Aβ42 level (pg/mL) Alzheimer’s disease Dementia due to other causes
Median Range Median Range
Sample size 73 30–142 41 26–134
Eﬀect size −442 −652–−41.200 −193 −356–−33
Table 6: Pooled estimate of eﬀect size with 95% CI, test of signiﬁcance, and magnitude of heterogeneity of CSF Aβ42 studies in Alzheimer’s
disease and dementia due to other causes.
Statistics Alzheimer’s disease Dementia due to other causes
Pooled estimate of CSF Aβ42 (pg/mL) −363.926 −170.743
95% CI of pooled estimate (pg/mL) −542.007–−185.845 −256.912–−84.574
Between-studies variance (T2) 54859.742 9755.39
Degree of heterogeneity (I2) 97.8% 83.7%
95% CI of I2 96.8%–98.5% 69.7%–91.7%
Q statistics 271.051 36.780
DF 6 6
P value 0.000 0.000
strongly recommend the presence of heterogeneity in a set of
11 tau studies (Table 3). The test of signiﬁcance (P = 0.000)
suggests the presence of true heterogeneity among the eﬀect
sizeofall11studies.Themagnitudeofthetrueheterogeneity
due to between studies variance (T2 = 85013.958 for AD
versus controls, & 4343.165 for DOC versus controls) was
much higher and contributed to 97.9% in AD versus control
and 82.4% in DOC versus control (degree of heterogeneity
I2) in total heterogeneity. All the studies selected, fulﬁlling
the deﬁned inclusion criteria, report a signiﬁcant diﬀerence
in CSF tau levels in AD and DOC participants versus
controls. Despite the uniform pattern of CSF tau level
c h a n g e si nA Da n dD O Ca sc o m p a r e dt oc o n t r o l ,t h e r ew a s
wide range of eﬀect size among 11 articles under study in
ADgroup(32.02–910.00pg/mL)ascomparedtoDOCgroup
(−53.30–−518.00pg/mL). There were large diﬀerences in
baseline levels across studies; 6 studies’ in AD versus control
[13, 15, 18, 20, 22, 23] and 05 studies in DOC versus control
haveeﬀectsizemorethanpooledestimate[13,16,18,22,23],
signify that dementia patients having higher CSF tau levels
than control. However, the increase in CSF tau levels in AD
was much higher than in DOC as compared to control in
most studies. Only Ravaglia et al. 2008 [24]f o u n dl o we ﬀect
size (raw mean diﬀerence) of tau levels in DOC as compared
to AD. A number of confounding factors are responsible
for the heterogeneity and wide range of CI of eﬀect size
found in the studies undergoing meta-analysis. First, very
few studies could be included for meta-analysis as per the
inclusion criteria in the present study; second, except one
study[17]allofthestudieshadverylowsamplesizeforDOC
group. Also most of the studies were not age-, sex-matched,
and of 11AD studies, 7 studies were having more number of
cases than controls [13, 16–18, 20–22] while in 4 studies the
numberofcontrolwaseitherequalormorethanthenumber
of cases [15, 19, 23, 24]. Similarly, in DOC group, 6 studies
were having more number of cases than controls [13, 16–
18, 21, 22]. There are inconsistent ﬁndings reported showing
discrepancies in the eﬀect of these on CSF tau levels in AD
versus controls. Some investigators have reported increase of
tau with age [15, 19] and a negative correlation with sex [17]
with a tendency for females to have higher tau levels than
males whereas others found tau levels unaﬀected by age, age
at onset, and AD duration, severity, and rate of progression
and equally increased in early and late disease, in mild and
severe disease [17, 19, 21]. Another confounding factor is
variation in freezer shelf life introducing variation in storage
conditions for CSF.
4.2. Meta-Analysis of Amyloid β42 Level. All the published
studies undertaken in the present meta-analysis showed low
CSF Aβ42 levels in AD and DOC as compared to controls.
However, one study eﬀect size had wider conﬁdence interval
with upper limit more than zero in both AD and DOC
[21]. Table 5 shows that median eﬀect size of Aβ42 levels in
CSF in AD is −442pg/mL as compared to −193pg/mL in
DOC which indicates that decrease in CSF Aβ42 in AD is
much higher than in DOC group as compared to controls.
It is supported by the studies done in last two decades
reporting low CSF Aβ42 levels in early stages of AD with high
degreeofsensitivityandspeciﬁcity[25]ascomparedtoother
dementias-LBD [13]a n dV a D[ 13].
Out of 7 studies undertaken, 5 studies in AD versus
control group had more number of cases than controls
[13, 17, 20–22] while the other 2 studies had either equal
number of controls or less than cases [19, 23], whereas in
DOC versus control group, only 2 studies had more number
of cases than controls [13, 17] and the other 5 studies had
either more or equal number of controls than cases [19–23].
Same three statistical techniques as have been applied in
CSF tau studies (mentioned above) were used to determine
the true heterogeneity (between-studies variability) in eﬀect
size of 7 included studies (Table 6). The test of signiﬁcance
(P = 0.000) rejects the null hypothesis of similar eﬀect8 International Journal of Alzheimer’s Disease
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Figure 2: (a) CSF Amyloid β(1–42) level in Alzheimer’s disease. (b) CSF amyloid β(1–42) level in dementia due to other causes.
size in all the studies, and the estimated between-studies
variance (between studies variance T2 = 54859.742 for AD
versus controls and 9755.039 for DOC versus controls) was
very much high and between-studies variance contributes
the most in total heterogeneity (degree of heterogeneity I2 =
97.8, CI: 96.8%–98.5% in AD and degree of heterogeneity
I2 = 83.7, CI: 67.9%–91.7% in DOC). The heterogeneity
in eﬀect size of these 07 published studies could be due
to diﬀerent population, small sample size and lack of
standardization of assay methods [26]. Though in AD group
all 7 studies showed signiﬁcant reductions in CSF Aβ42 levels
as compared to control participants, the result of the present
study was unequivocal and the range of eﬀect size of 7
studies was quite large (−652 to −41.2pg/mL). However,
the fall in DOC group was much lower than in AD when
compared to the control with reduced range of eﬀect size
of 7 studies undertaken (−33 to −356pg/mL). Due to wide
range of eﬀect size of these studies, 2 studies eﬀect size was
more [19, 21] and that of 5 studies was less than the pooled
estimate [17, 20, 22, 23] whereas 1 study [13] was on the
vertical line passing through the pooled eﬀect size. Similarly,
inDOCgroup,2studieseﬀectsizewasmore[19,21]andthat
of 5 studies was less than the pooled estimate [13, 17, 22, 23]
whereas 1 study [20] was on the vertical line passing through
the pooled eﬀect size.
It has been a challenging task to explain the wide varia-
tion in results in the diﬀerent laboratories due to technical
problems in the studies included for studying the diagnostic
utility of CSF biomarkers tau and Aβ42 in dementia. To
overcome this, sensitivity analysis was conducted to explore
the sensitivity level of each study. It was observed that there
was not much diﬀerence in overall eﬀect size on exclusion
of one study at a time. Another major problem with this
meta-analysis study is the presence of “publication bias.”
Several lines of evidence show [27] that studies that report
relativelyhigheﬀectsizesaremorelikelytobepublishedthanInternational Journal of Alzheimer’s Disease 9
studies that report lower eﬀect sizes. In the present study,
Funnel plot analysis was done which showed the presence
of publication bias for both parameters in AD as well as
DOC group supporting the hypothesis that any bias in the
literature is likely to be reﬂected in the meta-analysis study
as only statistically signiﬁcant results are more likely to be
published.
4.3. Limitation. During the present meta-analysis, a number
offactorswasobservedwhichcouldbecausingthelimitation
in developing hypothesis/coming to conclusion regarding
using CSF tau and Aβ42 as diagnostic markers in diﬀerential
diagnosis of AD from dementias due to other causes. One
limitation encountered during the present study was simply
the amount of eﬀort and expertise meta-analysis takes. Also,
lack of complete information in some studies and high
level of heterogeneity in individual study eﬀect size for both
parameters (tau & Aβ42) added to the limitation. Variation
in CSF tau and Aβ42 levels in AD, DOC, and controls may
be due to the variability introduced during sample collection
and storage like using glass or polystyrene tubes18 than
polypropylene tubes, prolonged storage of CSF samples in
frozen state or repeated freezing and thawing of CSF, errors
introduced due to inadequate study plan like small sample
size, less number of controls taken in the study as compared
to cases, or case and controls being not age and sex matched
[24].
5. Conclusion
Based on our ﬁndings of the present meta-analysis, it can be
concluded that the combination of high tau and low Aβ42
is highly speciﬁc for AD and might be useful in screening
out the suspected cases of AD, from other types of dementia.
However, due to the limited number of studies having large
number of sample size with age- and sex-matched samples in
controlandcasesavailable,theuseofthesebiomarkershasto
be veriﬁed in further prospective studies.
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